Researching: Compare CRISPR-Cas9 and CRISPR-Cas12 for in vivo gene editing. {"question": "Compare CRISPR-Cas9 and CRISPR-Cas12 for in vivo gene editing.", "depth": "balanced", "max_iterations": null, "token_budget": null, "event": "ask_started", "logger": "marchwarden.cli", "level": "info", "timestamp": "2026-04-09T01:57:22.951394Z"} {"transport": "stdio", "server": "marchwarden-web-researcher", "event": "mcp_server_starting", "logger": "marchwarden.mcp", "level": "info", "timestamp": "2026-04-09T01:57:23.942406Z"} {"event": "Processing request of type CallToolRequest", "logger": "mcp.server.lowlevel.server", "level": "info", "timestamp": "2026-04-09T01:57:23.953465Z"} {"question": "Compare CRISPR-Cas9 and CRISPR-Cas12 for in vivo gene editing.", "depth": "balanced", "max_iterations": 5, "token_budget": 20000, "model_id": "claude-sonnet-4-6", "event": "research_started", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.web", "level": "info", "timestamp": "2026-04-09T01:57:24.008304Z"} {"step": 1, "decision": "Beginning research: depth=balanced", "question": "Compare CRISPR-Cas9 and CRISPR-Cas12 for in vivo gene editing.", "context": "", "max_iterations": 5, "token_budget": 20000, "event": "start", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:57:24.008814Z"} {"step": 2, "decision": "Starting iteration 1/5", "tokens_so_far": 0, "event": "iteration_start", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:57:24.008920Z"} {"step": 7, "decision": "Starting iteration 2/5", "tokens_so_far": 1180, "event": "iteration_start", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:57:42.087229Z"} {"step": 14, "decision": "Starting iteration 3/5", "tokens_so_far": 12270, "event": "iteration_start", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:57:47.632253Z"} {"step": 21, "decision": "Token budget reached before iteration 4: 25966/20000", "event": "budget_exhausted", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:57:55.072818Z"} {"step": 22, "decision": "Beginning synthesis of gathered evidence", "evidence_count": 24, "iterations_run": 3, "tokens_used": 25966, "event": "synthesis_start", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:57:55.072985Z"} {"step": 23, "decision": "Parsed synthesis JSON successfully", "duration_ms": 89456, "event": "synthesis_complete", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:59:21.172200Z"} {"step": 46, "decision": "Research complete", "confidence": 0.82, "citation_count": 14, "gap_count": 4, "discovery_count": 4, "total_duration_sec": 121.701, "event": "complete", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.trace", "level": "info", "timestamp": "2026-04-09T01:59:21.274347Z"} {"confidence": 0.82, "citations": 14, "gaps": 4, "discovery_events": 4, "tokens_used": 54153, "iterations_run": 3, "wall_time_sec": 117.15539288520813, "budget_exhausted": true, "event": "research_completed", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.web", "level": "info", "timestamp": "2026-04-09T01:59:21.275590Z"} {"error": "[Errno 13] Permission denied: '/home/micro/.marchwarden/costs.jsonl'", "event": "cost_ledger_write_failed", "trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "researcher": "web", "logger": "marchwarden.researcher.web", "level": "warning", "timestamp": "2026-04-09T01:59:21.286942Z"} {"event": "Processing request of type ListToolsRequest", "logger": "mcp.server.lowlevel.server", "level": "info", "timestamp": "2026-04-09T01:59:21.531952Z"} {"trace_id": "9e436db7-fcde-4d0f-a568-c468ae4d419c", "confidence": 0.82, "citations": 14, "tokens_used": 54153, "wall_time_sec": 117.15539288520813, "event": "ask_completed", "logger": "marchwarden.cli", "level": "info", "timestamp": "2026-04-09T01:59:22.766505Z"} ╭─────────────────────────────────── Answer ───────────────────────────────────╮ │ CRISPR-Cas9 and CRISPR-Cas12a (formerly Cpf1) are both widely used │ │ RNA-guided nucleases adapted for genome editing, including in vivo │ │ applications, but they differ meaningfully in mechanism, structure, PAM │ │ requirements, cutting pattern, guide RNA architecture, specificity, and │ │ practical suitability for in vivo delivery. │ │ │ │ **Mechanism and DNA Cleavage:** Cas9 (most commonly from Streptococcus │ │ pyogenes, SpCas9) cleaves both DNA strands at the same position, producing │ │ blunt-ended double-strand breaks (DSBs) [Source 7]. Cas12a, by contrast, │ │ introduces staggered cuts that leave 4–5 nucleotide 5′ overhangs [Sources 2, │ │ 7]. These sticky ends generated by Cas12a may enhance homology-directed │ │ repair (HDR) efficiency compared to Cas9's blunt ends [Source 2]. │ │ │ │ **PAM Sequence:** Cas9 requires an NGG PAM (protospacer adjacent motif) on │ │ the non-template strand downstream of the target; Cas12a recognizes a T-rich │ │ PAM (typically TTTV) upstream of the target on the non-template strand │ │ [Sources 2, 7]. This difference expands the targeting range of Cas12a to │ │ AT-rich genomic regions where Cas9 is limited. │ │ │ │ **Guide RNA:** Cas9 uses a two-component guide (crRNA + tracrRNA, often │ │ fused as sgRNA), while Cas12a requires only a single crRNA with a short │ │ direct repeat and processes its own pre-crRNA array, enabling multiplexed │ │ editing from a single transcript [Sources 2, 7, 13]. │ │ │ │ **Specificity and Off-Target Effects:** Kinetic studies show Cas12a exhibits │ │ greater target specificity than Cas9, attributed to a more stringent DNA │ │ unwinding mechanism that requires more extensive complementarity before │ │ cleavage [Source 5]. Cas12a tolerates fewer mismatches between the guide RNA │ │ and target, resulting in fewer off-target cuts [Sources 2, 5]. │ │ │ │ **Editing Efficiency:** In comparative studies using ribonucleoprotein (RNP) │ │ delivery in rice (OsPDS gene), Cas9 and Cas12a showed different efficiencies │ │ depending on the target site [Source 1]. In Chlamydomonas reinhardtii, both │ │ Cas9 and Cas12a RNPs co-delivered with ssODN repair templates achieved │ │ similar total editing levels of 20–30% [Source 4]. Context and target site │ │ selection significantly influence which enzyme performs better. │ │ │ │ **In Vivo Delivery Considerations:** Both enzymes can be delivered via AAV │ │ vectors, lipid nanoparticles (LNPs), or as RNPs via electroporation [Sources │ │ 21, 24]. A critical practical consideration is size: SpCas9 (~4.2 kb coding │ │ sequence) is near the AAV packaging limit (~4.7–4.8 kb), leaving little room │ │ for promoter and regulatory elements [Sources 20, 21]. Cas12a variants │ │ (including engineered compact forms such as EbCas12a) can be packaged │ │ together with their crRNA within a single AAV vector, which is a significant │ │ advantage for in vivo delivery [Sources 19, 20, 21]. A miniature Cas12f1 │ │ variant has also demonstrated efficacy for in vivo retinal gene therapy │ │ [Source 12]. │ │ │ │ **Clinical and Therapeutic Status:** CRISPR-Cas9 is currently the dominant │ │ nuclease in clinical trials for both ex vivo and in vivo genome editing │ │ [Sources 8, 11]. Cas12a is gaining traction in therapeutic research, │ │ particularly where higher specificity or AAV-compatible delivery is required │ │ [Sources 9, 13, 22]. │ │ │ │ **Summary Table:** │ │ - DNA cut type: Cas9 = blunt; Cas12a = staggered (5′ overhang) │ │ - PAM: Cas9 = NGG (3′); Cas12a = TTTV (5′) │ │ - Guide RNA: Cas9 = sgRNA (crRNA+tracrRNA); Cas12a = crRNA only │ │ - Multiplexing: Cas9 = limited; Cas12a = inherent crRNA array processing │ │ - Specificity: Cas12a generally higher │ │ - AAV compatibility: Cas12a variants better suited │ │ - Clinical use: Cas9 more established; Cas12a emerging │ ╰──────────────────────────────────────────────────────────────────────────────╯ Citations ┏━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┳━━━━━━━┓ ┃ # ┃ Title / Locator ┃ Excerpt ┃ Conf ┃ ┡━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━╇━━━━━━━┩ │ 1 │ What's the Difference Between │ Cas9...cleaves both strands of │ 0.95 │ │ │ Cas9 and Cas12a Nucleases? | │ DNA at the same point. This │ │ │ │ The Scientist │ creates a blunt end │ │ │ │ https://www.the-scientist.com │ double-stranded break (DSB)... │ │ │ │ /what-s-the-difference-betwee │ For Cas9 to function, the │ │ │ │ n-cas9-and-cas12a-nucleases-7 │ protospacer adjacent motif │ │ │ │ 2481 │ (PAM)—a two to six base pair │ │ │ │ │ sequence—NGG...must sit │ │ │ │ │ immediately downstream of the │ │ │ │ │ target on the opposite strand. │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 2 │ Cas9 versus Cas12a/Cpf1: │ Cas9 and Cas12a have distinct │ 0.97 │ │ │ Structure-function │ evolutionary origins and │ │ │ │ comparisons and implications │ exhibit different structural │ │ │ │ for genome editing - PubMed │ architectures, resulting in │ │ │ │ https://pubmed.ncbi.nlm.nih.g │ distinct molecular │ │ │ │ ov/29790280/ │ mechanisms... We discuss │ │ │ │ │ implications for genome │ │ │ │ │ editing, and how they may │ │ │ │ │ influence the choice of Cas9 │ │ │ │ │ or Cas12a for specific │ │ │ │ │ applications. │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 3 │ CRISPR-Cas12a More Precise │ Cas12a...is, according to │ 0.90 │ │ │ Than CRISPR-Cas9 │ scientists at the University │ │ │ │ https://www.genengnews.com/to │ of Texas at Austin │ │ │ │ pics/genome-editing/crispr-ca │ (UT-Austin), more effective │ │ │ │ s12a-more-precise-than-crispr │ and precise... Because Cas │ │ │ │ -cas9/ │ enzymes occasionally fail to │ │ │ │ │ cut DNA in the right places, │ │ │ │ │ or even cut at all, they worry │ │ │ │ │ developers, who want to modify │ │ │ │ │ genomes with surgical │ │ │ │ │ precision, especially in │ │ │ │ │ therapeutic applications. │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 4 │ Comparison of CRISPR/Cas9 and │ We found that Cas9 and Cas12a │ 0.92 │ │ │ Cas12a for gene editing in │ RNPs- co-delivered with ssODN │ │ │ │ Chlamydomonas reinhardtii - │ repair templates- induced │ │ │ │ ScienceDirect │ similar levels of total │ │ │ │ https://www.sciencedirect.com │ editing, achieving as much as │ │ │ │ /science/article/pii/S2211926 │ 20–30 % in all │ │ │ │ 424004089 │ │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 5 │ Comparison of │ Comparison of │ 0.88 │ │ │ CRISPR-Cas9/Cas12a │ CRISPR-Cas9/Cas12a │ │ │ │ Ribonucleoprotein Complexes │ Ribonucleoprotein Complexes │ │ │ │ for Genome Editing Efficiency │ for Genome Editing Efficiency │ │ │ │ in the Rice Phytoene │ in the Rice Phytoene │ │ │ │ Desaturase (OsPDS) Gene - PMC │ Desaturase (OsPDS) Gene │ │ │ │ https://pmc.ncbi.nlm.nih.gov/ │ │ │ │ │ articles/PMC6973557/ │ │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 6 │ Current and Prospective │ Current and Prospective │ 0.87 │ │ │ Applications of CRISPR-Cas12a │ Applications of CRISPR-Cas12a │ │ │ │ in Pluricellular Organisms - │ in Pluricellular Organisms... │ │ │ │ PMC │ Mol Biotechnol. 2022 Aug │ │ │ │ https://pmc.ncbi.nlm.nih.gov/ │ 8;65(2):196–205. doi: │ │ │ │ articles/PMC9841005/ │ 10.1007/s12033-022-00538-5 │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 7 │ When size matters: A novel │ When size matters: A novel │ 0.90 │ │ │ compact Cas12a variant for in │ compact Cas12a variant for in │ │ │ │ vivo genome editing - PMC │ vivo genome editing │ │ │ │ https://pmc.ncbi.nlm.nih.gov/ │ │ │ │ │ articles/PMC11253977/ │ │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 8 │ When size matters: A novel │ Altogether, the components of │ 0.91 │ │ │ compact Cas12a variant for in │ the EbCas12a system are well │ │ │ │ vivo genome editing - │ below the 4.8-kb packaging │ │ │ │ ResearchGate │ limit of AAVs, enabling │ │ │ │ https://www.researchgate.net/ │ successful packaging in the │ │ │ │ publication/382328745_When_si │ AAV9 │ │ │ │ ze_matters_A_novel_compact_Ca │ │ │ │ │ s12a_variant_for_in_vivo_geno │ │ │ │ │ me_editing │ │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 9 │ Therapeutic In Vivo Gene │ our current results prove that │ 0.88 │ │ │ Editing Achieved by a │ the miniature Cas12f1 system │ │ │ │ Hypercompact CRISPR System - │ is a promising gene editing │ │ │ │ Advanced Science │ tool for retinal gene therapy │ │ │ │ https://advanced.onlinelibrar │ │ │ │ │ y.wiley.com/doi/10.1002/advs. │ │ │ │ │ 202308095 │ │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 10 │ Delivery of CRISPR-Cas tools │ AAV is one of the most │ 0.90 │ │ │ for in vivo genome editing │ commonly used vector systems │ │ │ │ therapy: Trends and │ to date, but immunogenicity │ │ │ │ challenges - ScienceDirect │ against capsid, liver toxicity │ │ │ │ https://www.sciencedirect.com │ at high dose, and potential │ │ │ │ /science/article/pii/S0168365 │ genotoxicity caused by │ │ │ │ 92200027X │ off-target mutagenesis and │ │ │ │ │ genomic integration remain │ │ │ │ │ unsolved. │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 11 │ CRISPR-Based Therapeutic │ These Cas proteins are more │ 0.87 │ │ │ Genome Editing - DSpace@MIT │ compatible with AAV delivery, │ │ │ │ https://dspace.mit.edu/bitstr │ enabling additional vector │ │ │ │ eam/handle/1721.1/138388.2/ni │ design options such as │ │ │ │ hms-1576523.pdf?sequence=4&is │ expanded promoter choices and │ │ │ │ Allowed=y │ a streamlined delivery. │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 12 │ Revolutionizing in vivo │ Genome editing using the │ 0.85 │ │ │ therapy with CRISPR/Cas │ CRISPR/Cas system has │ │ │ │ genome editing: │ revolutionized the field of │ │ │ │ breakthroughs, opportunities │ genetic engineering, offering │ │ │ │ and challenges - Frontiers │ unprecedented opportunities │ │ │ │ https://www.frontiersin.org/j │ for therapeutic applications │ │ │ │ ournals/genome-editing/articl │ in vivo. │ │ │ │ es/10.3389/fgeed.2024.1342193 │ │ │ │ │ /full │ │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 13 │ CRISPR Clinical Trials: A │ CRISPR Clinical Trials: A 2024 │ 0.80 │ │ │ 2024 Update - Innovative │ Update - Innovative Genomics │ │ │ │ Genomics Institute │ Institute (IGI) │ │ │ │ https://innovativegenomics.or │ │ │ │ │ g/news/crispr-clinical-trials │ │ │ │ │ -2024/ │ │ │ ├─────┼───────────────────────────────┼────────────────────────────────┼───────┤ │ 14 │ Alt-R CRISPR-Cas9 vs Cas12a │ The two most popular enzymes │ 0.83 │ │ │ systems | IDT │ used in CRISPR genome editing │ │ │ │ https://www.idtdna.com/pages/ │ are Cas9 and Cas12a (Cpf1). │ │ │ │ technology/crispr/crispr-geno │ These enzymes are highly │ │ │ │ me-editing/Alt-R-systems │ functional, do not require │ │ │ │ │ binding to other enzymes as is │ │ │ │ │ the case for type I CRISPR │ │ │ │ │ systems, and can be readily │ │ │ │ │ programmed to target the │ │ │ │ │ desired genomic DNA site. │ │ └─────┴───────────────────────────────┴────────────────────────────────┴───────┘ Gaps ┏━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┓ ┃ Category ┃ Topic ┃ Detail ┃ ┡━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┩ │ source_not_found │ Head-to-head in vivo │ Most comparative studies │ │ │ efficacy data in mammals │ focused on plants (rice) or │ │ │ across multiple tissue │ algae (Chlamydomonas) or │ │ │ types │ used in vitro/ex vivo │ │ │ │ models. Rigorous │ │ │ │ side-by-side in vivo │ │ │ │ mammalian comparisons of │ │ │ │ Cas9 vs. Cas12a across │ │ │ │ liver, muscle, CNS, and eye │ │ │ │ were not identified in │ │ │ │ available sources. │ ├──────────────────┼─────────────────────────────┼─────────────────────────────┤ │ source_not_found │ Immunogenicity comparison │ While immunogenicity of │ │ │ between Cas9 and Cas12a in │ Cas9 is well-documented as │ │ │ vivo │ a challenge for in vivo │ │ │ │ delivery, direct │ │ │ │ comparative immunogenicity │ │ │ │ data for Cas12a in humans │ │ │ │ or animal models was not │ │ │ │ available in the gathered │ │ │ │ sources. │ ├──────────────────┼─────────────────────────────┼─────────────────────────────┤ │ source_not_found │ Cas12a clinical trial data │ The IGI clinical trials │ │ │ │ update and other sources │ │ │ │ confirm Cas9 dominance in │ │ │ │ trials but do not provide │ │ │ │ details on approved or │ │ │ │ ongoing Cas12a-specific │ │ │ │ clinical trials. │ ├──────────────────┼─────────────────────────────┼─────────────────────────────┤ │ source_not_found │ Detailed off-target │ While Cas12a is reported to │ │ │ profiling comparison in │ be more specific than Cas9 │ │ │ vivo │ based on kinetic studies, │ │ │ │ comprehensive in vivo │ │ │ │ off-target profiling │ │ │ │ comparing both enzymes │ │ │ │ systematically across the │ │ │ │ same targets was not │ │ │ │ available in the sources. │ └──────────────────┴─────────────────────────────┴─────────────────────────────┘ Discovery Events ┏━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━┓ ┃ ┃ Suggested ┃ ┃ ┃ ┃ Type ┃ Researcher ┃ Query ┃ Reason ┃ ┡━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━┩ │ related_research │ arxiv │ Cas12a vs Cas9 in │ Head-to-head in │ │ │ │ vivo editing │ vivo mammalian │ │ │ │ efficiency │ comparisons are a │ │ │ │ off-target │ critical gap; │ │ │ │ mammalian │ preprint servers │ │ │ │ therapeutic │ may have more │ │ │ │ comparison 2023 │ recent │ │ │ │ 2024 │ unpublished data │ ├──────────────────┼───────────────────┼───────────────────┼───────────────────┤ │ related_research │ database │ CRISPR Cas12a │ Clinical adoption │ │ │ │ clinical trials │ of Cas12a in vivo │ │ │ │ ClinicalTrials.go │ is poorly │ │ │ │ v 2023 2024 │ characterized; a │ │ │ │ │ ClinicalTrials.go │ │ │ │ │ v database search │ │ │ │ │ would clarify │ │ │ │ │ current status │ ├──────────────────┼───────────────────┼───────────────────┼───────────────────┤ │ related_research │ arxiv │ Cas12a │ Immunogenicity is │ │ │ │ immunogenicity │ a key barrier for │ │ │ │ pre-existing │ in vivo Cas9 │ │ │ │ immunity in vivo │ delivery; whether │ │ │ │ gene therapy │ Cas12a poses │ │ │ │ human │ fewer immune │ │ │ │ │ challenges is │ │ │ │ │ clinically │ │ │ │ │ important but not │ │ │ │ │ covered in │ │ │ │ │ sources │ ├──────────────────┼───────────────────┼───────────────────┼───────────────────┤ │ new_source │ database │ compact Cas12a │ Compact Cas12a │ │ │ │ EbCas12a AsCas12a │ variants show │ │ │ │ in vivo liver │ promise for AAV │ │ │ │ lung CNS │ delivery; recent │ │ │ │ therapeutic │ therapeutic in │ │ │ │ editing 2024 │ vivo data would │ │ │ │ │ strengthen the │ │ │ │ │ comparison │ └──────────────────┴───────────────────┴───────────────────┴───────────────────┘ Open Questions ┏━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┓ ┃ Priority ┃ Question ┃ Context ┃ ┡━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┩ │ high │ Does Cas12a's staggered cutting │ Sources note that staggered │ │ │ pattern result in meaningfully │ cuts may enhance HDR, but │ │ │ higher HDR rates than Cas9's │ comparative in vivo HDR │ │ │ blunt cuts in vivo in │ efficiency data in mammals was │ │ │ therapeutically relevant cell │ not found in the gathered │ │ │ types? │ evidence. │ ├──────────┼─────────────────────────────────┼─────────────────────────────────┤ │ high │ Are there pre-existing │ Immunogenicity is a known │ │ │ antibodies or T-cell responses │ challenge for Cas9 in vivo; │ │ │ against Cas12a proteins in │ whether Cas12a, being from │ │ │ humans that would limit its │ different bacterial origins, │ │ │ therapeutic use, as has been │ faces similar or lesser immune │ │ │ documented for SpCas9? │ barriers in human patients is │ │ │ │ clinically critical. │ ├──────────┼─────────────────────────────────┼─────────────────────────────────┤ │ high │ Can compact Cas12a variants │ Compact variants fit within AAV │ │ │ (e.g., EbCas12a, Cas12f) │ packaging limits better than │ │ │ consistently match or exceed │ Cas9, but their in vivo editing │ │ │ SpCas9 editing efficiency in │ efficiency relative to SpCas9 │ │ │ vivo across diverse tissue │ across tissues such as liver, │ │ │ types? │ muscle, and CNS needs │ │ │ │ systematic evaluation. │ ├──────────┼─────────────────────────────────┼─────────────────────────────────┤ │ medium │ How does Cas12a's inherent │ Cas12a can process its own │ │ │ crRNA array processing and │ pre-crRNA array, enabling │ │ │ multiplexing capability │ multiplexed targeting from a │ │ │ translate to in vivo │ single transcript, which is │ │ │ combinatorial therapeutic │ noted as an advantage but its │ │ │ strategies compared to │ in vivo therapeutic │ │ │ Cas9-based multiplex │ exploitation is not │ │ │ approaches? │ well-characterized in available │ │ │ │ sources. │ ├──────────┼─────────────────────────────────┼─────────────────────────────────┤ │ medium │ What is the current status of │ The 2024 CRISPR clinical trials │ │ │ Cas12a-specific clinical trials │ update from IGI and Frontiers │ │ │ for in vivo gene therapy, and │ review both highlight Cas9 │ │ │ how do their safety profiles │ dominance in clinical trials, │ │ │ compare to Cas9-based trials? │ but Cas12a clinical translation │ │ │ │ remains poorly documented. │ └──────────┴─────────────────────────────────┴─────────────────────────────────┘ ╭───────────────────────────────── Confidence ─────────────────────────────────╮ │ Overall: 0.82 │ │ Corroborating sources: 14 │ │ Source authority: high │ │ Contradiction detected: False │ │ Query specificity match: 0.85 │ │ Budget status: spent │ │ Recency: current │ ╰──────────────────────────────────────────────────────────────────────────────╯ ╭──────────────────────────────────── Cost ────────────────────────────────────╮ │ Tokens: 54153 │ │ Iterations: 3 │ │ Wall time: 117.16s │ │ Model: claude-sonnet-4-6 │ ╰──────────────────────────────────────────────────────────────────────────────╯ trace_id: 9e436db7-fcde-4d0f-a568-c468ae4d419c